scholarly journals SERUM LIPOPROTEINS AND CHRONIC HEPATITIS C INFECTION;

2018 ◽  
Vol 21 (02) ◽  
pp. 302-306
Author(s):  
Jahangir Liaquat ◽  
. Muhammad Adnan Bawany ◽  
Shuaib Ansari ◽  
Adnan Ali Khahro ◽  
Falak Naz ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Lipid Profile ◽  
Chronic Hepatitis C ◽  
Serum Lipid ◽  
The Body ◽  
University Hospital ◽  
Serum Lipid Profile ◽  
Diabetic Patients ◽  
Number Of Patients

Objectives: To determine the serum lipid profile in patients with chronic HCVinfection and correlation between serum lipid levels and liver histology. Material and methods:Descriptive study was carried out in Medical Unit I of Liaquat University Hospital JamshoroHyderabad, from September 2007 to August 2009. Convenience sampling was used and 30patients were selected. Positive PCR test for HCV, non diabetic patients and non cirrhotic patientswere included in this study. All the patients were selected from the medical OPD. Clinicalexamination performed and then blood tests were done. Serum lipid profile were determined inall participants after an overnight fast of 12 h. TC, TG, and HDL-C was measured enzymaticallywith commercial kits (Olympus System Reagent, Hamburg, Germany) by the use of anautomated analyzer. The body mass index (BMI) was calculated in accordance with the formulaof weight (kg) divided by height2 (m2). Selected patients were called in the ward and biopsy wasdone via Trucut needle and the specimen was fixed in formalin. The biopsies were used tocalculate the degree of steatosis (0-3) and fibrosis by METAVIR score. Results: A total of 30patients were selected for this study. Out of these 19 were males and 11 females. The patientswere divided in three groups. Patients with chronic HCV infection were found to have significantlylower levels of serum TC, HDL-C and LDL-C than normal adults values. Steatosis was present insignificant number of patients (36.67%). However, steatosis was not correlating with fibrosis(p>0.005). Conclusions: Hypolipoproteinemia and steatosis are important factors which areassociated with chronic hepatitis C

Assessment of Serum Lipid Profile in patients with chronic Hepatitis C

2018 ◽  
Vol 8 (8) ◽  
Author(s):  
Tanveer Ul Hassan ◽  
Bilal Umar ◽  
Danish Malik ◽  
Shoaib Waris ◽  
Khalid Hussain ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Lipid Profile ◽  
Chronic Hepatitis C ◽  
Serum Lipid ◽  
Serum Lipid Profile

scholarly journals Evaluation of Serum Lipid Profile in Turkish Patients with Chronic Hepatitis C

2011 ◽  
Vol 8 (1) ◽  
Author(s):  
Mustafa Güçlü ◽  
Hakan Sakallı ◽  
Tolga Yakar ◽  
Nurzen Sezgin ◽  
Murat Gülşen
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Lipid Profile ◽  
Chronic Hepatitis C ◽  
Serum Lipid ◽  
Serum Lipid Profile ◽  
Turkish Patients

scholarly journals Serum lipid profile and chronic hepatitis C virus

Hepatology ◽  
2010 ◽  
Vol 53 (2) ◽  
pp. 716-717
Author(s):  
Tugrul Purnak ◽  
Cumali Efe ◽  
Yavuz Beyazit ◽  
Ersan Ozaslan
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lipid Profile ◽  
Chronic Hepatitis C ◽  
Serum Lipid ◽  
Serum Lipid Profile ◽  
Chronic Hepatitis C Virus

scholarly journals Efficacy of velpatasvir and sofosbuvir in treatment of chronic hepatitis C.

2021 ◽  
Vol 28 (02) ◽  
pp. 153-157
Author(s):  
Muhammad Badar Bashir ◽  
Hafiz Bilal Bashir ◽  
Mahpara Munir
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
University Hospital ◽  
Fixed Dose ◽  
Descriptive Case Study ◽  
Number Of Patients ◽  
Dose Combination ◽  
Chronic Hcv ◽  
Independent University

Objective: To determine the efficacy of sofosbuvir and velpatasvir in treatment of all genotypes of chronic HCV infection. Study Design: Descriptive Case study Setting: Department of Medicine Independent University Hospital Faisalabad. Period: December 2019 to May 2020. Material & Methods: Among patients of chronic hepatitis C presenting in the medical OPD of independent university hospital willing to participate, 80 were included in this study. They were given combination of sofosbuvir and velpatasvir 400/100 mg (FDC) once daily. They were monitored by serum ALT and PCR to HCV quantitative after one month and after three months. End point was undectable PCR to HCV Quantitative. We observed the number of patients achieving SVR after taking combination of sofosbuvir and velpatasvir. Results: In our study, out of 80 cases of chronic hepatitis c 40% (n=32) were male and 60% (n=48) were females, end result revealed 98.8% (n=79) achieved SVR and their PCR remained negative at the end of 03months and 1.3% (n=01) remained positive despite antiviral therapy for 03 months. Conclusion: We concluded that using fixed dose combination of sofosbuvir and velpatasvir achieve SVR of 98.8%.

scholarly journals Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents

PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0209216 ◽  
Author(s):  
Alessandro Gualerzi ◽  
Mattia Bellan ◽  
Carlo Smirne ◽  
Margherita Tran Minh ◽  
Cristina Rigamonti ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Insulin Sensitivity ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Diabetic Patients ◽  
Direct Antiviral Agents

scholarly journals Distribution of hepatitis C virus genotypes and subtypes in a group of patients with chronic hepatitis C from Canton Sarajevo, 2012-2018

2019 ◽  
Vol 49 ◽  
Author(s):  
Irma Salimović- Bešić ◽  
Adna Kahriman ◽  
Suzana Arapčić ◽  
Amela Dedeić- Ljubović
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hcv Rna ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotypes ◽  
Number Of Patients ◽  
Subtype 1B

Background: Hepatitis C virus (HCV) genotypes and subtypes exhibit significant geographic variations.Aim: To analyse the distribution of genotypes/subtypes of HCV in a group of patients with chronic hepatitis C from Canton Sarajevo during 2012-2018.Material and methods:The study enrolled 247 human plasma samples of HCV-RNA positive patients with available results of HCV genotyping test.Results: During 2012-2018, the domination of subtypes 1a (34.01%), 1b (28.34%) and genotype 3 (23.89%) was registered. In 2012 and 2013, HCV subtype 1a was the most common (27/63; 42.86% and 17/40; 42.50%, respectively). In 2014, the leading HCV genotype/subtype were 3 and 1b (17/57; 29.82%). In 2015, the dominance of HCV genotype 3 (14/39; 35.90%) continued, while in 2016, the same number of HCV subtypes 1a and 1b (11/30; 36.67%) was recorded. Although in a small number of tested, during 2017, HCV subtype 1b was the most prevalent (7/14; 50.00%), and in 2018, it was replaced by a HCV subtype 1a (3/4; 75.00%). Distribution of HCV genotypes/subtypes by age group of patients varied significantly (p=0.000). The largest number of patients (71/247; 28.74%) belonged to the age category 30-39 years and HCV genotypes/subtypes 1, 3, 4, 1a and 1b were identified. Except in 2017, male gender significantly dominated (p=0.000). In males, HCV subtype 1a (68/170; 40.00%) was the most common, while in women it was HCV subtype 1b (44/77; 57.14%).Conclusion: This six-year retrospective study showed the time variations of the circulating HCV genotypes/subtypes among patients with chronic hepatitis C in Canton Sarajevo. Genotyping of the HCV has an important implications for diagnosis and treatment of the patients.

scholarly journals Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment

2020 ◽  
Vol 28 ◽  
pp. 204020662097483
Author(s):  
Sun Hee Lee ◽  
Hyun Phil Shin ◽  
Joung Il Lee
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Liver Stiffness ◽  
Serum Biomarkers ◽  
Post Treatment ◽  
Direct Acting Antivirals ◽  
Number Of Patients ◽  
Direct Acting

Background Recently, new direct-acting antivirals (DAAs) are known to eradicate chronic hepatitis C (CHC) virus infection and prevent the progression of liver fibrosis. Liver fibrosis may predispose to liver cirrhosis or hepatocellular carcinoma. We investigated the effect of DAAs on liver fibrosis using non-invasive methods, and evaluated the correlations of these methods. Methods We retrospectively analyzed 68 patients with CHC who were treated with DAAs and reached sustained virologic response at 12 weeks post-treatment from January 2016 to October 2018. The degree of liver fibrosis was assessed using serum biomarkers, such as AST-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) index. Liver stiffness was assessed using two-dimensional shear-wave elastography (2 D-SWE). The pre- and post-treatment serum biomarker levels and SWE findings were evaluated and compared. Results A total of 68 patients with CHC were enrolled. The median age was 58 years (52.3–73 years) and 37 patients (54.4%) were female. After treatment, the median APRI was decreased from 0.701 to 0.328 (P < 0.0001), and the median FIB-4 was decreased from 2.355 to 1.860 (P < 0.0001). The median kPa in 2 D-SWE significantly reduced from 6.85 to 5.66 (P = 0.013). APRI and FIB-4 were significantly correlated pre- and post-treatment; however, the correlation between the serum biomarkers and 2 D-SWE was partially significant. Conclusion The serum fibrosis biomarkers and liver stiffness on 2 D-SWE were shown to be improved after the treatment with DAAs. Further research including larger number of patients is needed to compare the efficacy of each evaluating method.

Sign in / Sign up

Export Citation Format

Share Document